High-rolling investors have positioned themselves bullish on Novo Nordisk (NYSE:NVO), and it's important for retail traders to take note.This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in NVO often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Novo Nordisk. This is not a typical pattern.
The sentiment among these major traders is split, with 66% bullish and 11% bearish. Among all the options we identified, there was one put, amounting to $26,390, and 8 calls, totaling $868,304.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $145.0 for Novo Nordisk, spanning the last three months.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Novo Nordisk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Novo Nordisk's significant trades, within a strike price range of $100.0 to $145.0, over the past month.
Novo Nordisk Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
| NVO | CALL | TRADE | BULLISH | 09/27/24 | $4.9 | $4.0 | $4.7 | $140.00 | $493.5K | 103 | 2 |
| NVO | CALL | TRADE | BULLISH | 03/21/25 | $33.85 | $33.65 | $33.85 | $110.00 | $101.5K | 187 | 31 |
| NVO | CALL | SWEEP | BULLISH | 09/13/24 | $3.95 | $3.75 | $3.95 | $138.00 | $99.9K | 694 | 302 |
| NVO | CALL | SWEEP | BULLISH | 09/20/24 | $2.11 | $2.09 | $2.1 | $145.00 | $41.8K | 7.9K | 208 |
| NVO | CALL | TRADE | NEUTRAL | 11/15/24 | $40.65 | $38.65 | $39.56 | $100.00 | $39.5K | 6 | 10 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of Novo Nordisk
- Currently trading with a volume of 1,216,126, the NVO's price is up by 1.77%, now at $137.34.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 70 days.
Expert Opinions on Novo Nordisk
3 market experts have recently issued ratings for this stock, with a consensus target price of $160.0.
- Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Novo Nordisk with a target price of $160.
- Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
高额投资者已将自己定位为看好诺和诺德（纽约证券交易所代码：NVO），散户交易者注意这一点很重要。\ 这项活动今天通过Benzinga对公开期权数据的追踪引起了我们的注意。这些投资者的身份尚不确定，但是NVO的如此重大举措通常表明有人拥有特权信息。
今天，Benzinga的期权扫描仪发现了Novo Nordisk的9笔期权交易。这不是典型的模式。
这些主要交易者的情绪分歧，66％看涨，11％看跌。在我们确定的所有期权中，有一个看跌期权，金额为26,390美元，还有8个看涨期权，总额为868,304美元。
预期的价格走势
在评估了交易量和未平仓合约之后，很明显，主要市场走势者正在关注过去三个月诺和诺德在100.0美元至145.0美元之间的价格区间。
分析交易量和未平仓合约
检查交易量和未平仓合约为股票研究提供了至关重要的见解。这些信息是衡量Novo Nordisk期权在特定行使价下的流动性和利息水平的关键。下面，我们简要介绍了过去一个月诺和诺德重大交易的看涨期权和未平仓合约的趋势，行使价区间为100.0美元至145.0美元。
诺和诺德期权活动分析：过去 30 天
发现的最大选择：
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
NVO | CALL | TRADE | BULLISH | 09/27/24 | $4.9 | $4.0 | $4.7 | $140.00 | $493.5K | 103 | 2 |
NVO | CALL | TRADE | BULLISH | 03/21/25 | $33.85 | $33.65 | $33.85 | $110.00 | $101.5K | 187 | 31 |
NVO | CALL | SWEEP | BULLISH | 09/13/24 | $3.95 | $3.75 | $3.95 | $138.00 | $99.9K | 694 | 302 |
NVO | CALL | SWEEP | BULLISH | 09/20/24 | $2.11 | $2.09 | $2.1 | $145.00 | $41.8K | 7.9K | 208 |
NVO | CALL | TRADE | NEUTRAL | 11/15/24 | $40.65 | $38.65 | $39.56 | $100.00 | $39.5K | | |
关于 Novo Nordisk
诺和诺德拥有全球品牌糖尿病治疗市场约三分之一的份额，是全球领先的糖尿病护理产品提供商。该公司总部位于丹麦，生产和销售各种人用和现代胰岛素、注射型糖尿病治疗药物（如 GLP-1 疗法）、口服抗糖尿病药物和肥胖疗法。Novo还有一个生物制药板块（约占收入的10％），专门研究血友病和其他疾病的蛋白质疗法。
在对围绕Novo Nordisk的期权交易进行了全面审查之后，我们将对该公司进行更详细的审查。这包括评估其当前的市场状况和表现。
诺和诺德的当前位置
关于诺和诺德的专家意见
3位市场专家最近发布了该股的评级，共识目标价为160.0美元。
BMO Capital的一位分析师在评估中保持了对诺和诺德跑赢大盘的评级，目标价为160美元。
坎托·菲茨杰拉德的一位分析师将其评级下调至增持，新的目标股价为160美元，这反映了人们的担忧。
坎托·菲茨杰拉德的一位分析师谨慎地将其评级下调至增持，将目标股价定为160美元。
期权交易带来更高的风险和潜在的回报。精明的交易者通过不断自我教育、调整策略、监控多个指标以及密切关注市场走势来管理这些风险。通过Benzinga Pro的实时提醒，随时了解Novo Nordisk的最新期权交易。
